COST-EFFECTIVENESS OF SECOND-LINE NILOTINIB VERSUS DASATINIB FOR THE TREATMENT OF PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA-CHRONIC PHASE (PH plus CML-CP) IN ITALY

被引：0
|
作者：
Maheshwari, V [1 ]
Tran, D. [2 ]
Agostoni, G. [3 ]
Filioussi, K. [3 ]
Viana, R. [4 ]
机构：
[1] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
[2] Cornerstone Res Grp Inc, Burlington, ON, Canada
[3] Novartis Farma SpA, Origgio, Italy
[4] Novartis, East Hannover, NJ USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN176
引用
收藏
页码：S470 / S470
页数：1
相关论文
共 50 条
  • [1] Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy
    Bonifacio, Massimiliano
    Maheshwari, Vikalp
    Tran, Diana
    Agostoni, Gianluca
    Filioussi, Kalitsa
    Viana, Ricardo
    PHARMACOECONOMICS-OPEN, 2022, 6 (01) : 95 - 104
  • [2] Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy
    Massimiliano Bonifacio
    Vikalp Maheshwari
    Diana Tran
    Gianluca Agostoni
    Kalitsa Filioussi
    Ricardo Viana
    PharmacoEconomics - Open, 2022, 6 : 95 - 104
  • [3] COST-EFFECTIVENESS OF NILOTINIB VERSUS DASATINIB FOR THE SECOND LINE TREATMENT OF PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP), RESISTANT OR INTOLERANT TO IMATINIB, IN FRAME OF RUSSIAN HEALTHCARE SYSTEM
    Goyert, N.
    Tran, D.
    Efremova, E.
    Apostopoulos, C.
    Grima, D.
    VALUE IN HEALTH, 2017, 20 (09) : A441 - A441
  • [4] COST-EFFECTIVENESS OF NILOTINIB VERSUS IMATINIB AS FIRST-LINE TREATMENT FOR NEWLY DIAGNOSED PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE (CML-CP) IN RUSSIAN FEDERATION
    Yagudina, R.
    Kulikov, A.
    Komarov, I
    VALUE IN HEALTH, 2012, 15 (07) : A426 - A426
  • [5] Cost-effectiveness of nilotinib versus imatinib as first-line treatment for newly diagnosed patients with Philadelphia chromosome-positive (Ph plus ) chronic myeloid leukemia in the chronic phase (CML-CP): Swedish perspective
    Ovanfors, A.
    Stephens, J.
    Snedecor, S. J.
    Patel, D.
    Ji, X.
    Carpiuc, K. T.
    Coombs, J.
    Botteman, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] COST EFFECTIVENESS OF NILOTINIB VERSUS IMATINIB AS FIRST LINE TREATMENT FOR NEWLY DIAGNOSED HONG KONG (HK) PATIENTS WITH CHRONIC PHASE, PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE (CML-CP) IN HONG KONG
    Tse, V
    Liu, H.
    Botteman, M.
    Mcghee, S.
    Lee, V. W.
    Lee, K. K.
    VALUE IN HEALTH, 2012, 15 (04) : A217 - A218
  • [7] Twelve-Month Cost per Responder (CPR) Analysis of Nilotinib and Dasatinib As Front-Line Therapy in Patients with Philadelphia Chromosome-Positive (Ph plus ) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Guerin, Annie
    Revol, Cindy
    Ramanakumar, Agnihotram V.
    Foster, Rebekah
    Wu, Qiong
    Mhatre, Shivani K.
    Chen, Lei
    BLOOD, 2014, 124 (21)
  • [8] Nilotinib Vs Dasatinib As Second-Line Therapy in Patients with Philadelphia-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph plus CML-CP) Who Are Resistant or Intolerant to Imatinib: A Cost-Effectiveness Analysis (CEA) Based on Real-World Data
    Li, Nanxin
    Yang, Chelsey
    Fan, Liangyi
    Totev, Todor
    Guerin, Annie
    Chen, Lei
    BLOOD, 2015, 126 (23)
  • [9] Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data
    Li, Nanxin
    Yang, Xi
    Fan, Liangyi
    Totev, Todor
    Guerin, Annie
    Chen, Lei
    Bhattacharyya, Subrata
    Joseph, George
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (04) : 328 - 336
  • [10] Molecular Responses to Dasatinib and Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop
    Michor, Franziska
    Olshen, Adam
    Gonen, Mithat
    Jones, Dan
    Rios, Mary Beth
    O'Brien, Susan
    Cortes, Jorge
    BLOOD, 2008, 112 (11) : 1114 - 1115
12345